{
    "clinical_study": {
        "@rank": "43699", 
        "arm_group": {
            "arm_group_label": "Treatment (dabrafenib, trametinib, Hsp90 inhibitor AT13387)", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive dabrafenib PO BID and trametinib PO QD on days 1-28, and Hsp90 inhibitor AT13387 IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
        }, 
        "brief_summary": {
            "textblock": "This phase I trial studies the side effects and best dose of Hsp90 inhibitor AT13387 when\n      given together with dabrafenib and trametinib in treating patients with melanoma that has\n      spread to another place in the body or cannot be removed by surgery and has come back after\n      previous treatment (recurrent). Hsp90 inhibitor AT13387, dabrafenib, and trametinib may stop\n      the growth of tumor cells by blocking some of the enzymes needed for cell growth."
        }, 
        "brief_title": "Hsp90 Inhibitor AT13387, Dabrafenib, and Trametinib in Treating Patients With Recurrent Melanoma That is Metastatic or Cannot be Removed by Surgery", 
        "condition": [
            "Recurrent Melanoma", 
            "Stage IIIA Melanoma", 
            "Stage IIIB Melanoma", 
            "Stage IIIC Melanoma", 
            "Stage IV Melanoma"
        ], 
        "condition_browse": {
            "mesh_term": "Melanoma"
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To determine the maximum tolerated dose (MTD), toxicity, and safety profile of AT13387\n      (Hsp90 inhibitor AT13387) given weekly in combination with dabrafenib and trametinib in\n      patients with v-raf murine sarcoma viral oncogene homolog B (BRAF) inhibitor resistant,\n      BRAF-mutant metastatic or unresectable melanoma.\n\n      SECONDARY OBJECTIVES:\n\n      I. To obtain preliminary estimates of the objective response rate (ORR) and progression-free\n      survival (PFS) and document the 6-month PFS and 1-year overall survival (OS) of patients\n      with BRAF inhibitor resistant, BRAF-mutant metastatic or unresectable melanoma treated with\n      AT13387 given weekly in combination with dabrafenib and trametinib.\n\n      II. To describe the pharmacokinetics of treatment with dabrafenib, trametinib, and AT13387.\n\n      III. To explore pharmacodynamic effects of AT13387 given weekly in combination with\n      dabrafenib and trametinib to patients with BRAF inhibitor resistant, BRAF-mutant metastatic\n      or unresectable melanoma by comparing pre- and on-treatment biopsies.\n\n      OUTLINE: This is a dose-escalation study of Hsp90 inhibitor AT13387.\n\n      Patients receive dabrafenib orally (PO) twice daily (BID) and trametinib PO once daily (QD)\n      on days 1-28, and Hsp90 inhibitor AT13387 intravenously (IV) over 1 hour on days 1, 8, and\n      15. Courses repeat every 28 days in the absence of disease progression or unacceptable\n      toxicity.\n\n      After completion of study treatment, patients are followed up at 28 days."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients must have histologically confirmed, BRAF-mutant (V600E/K) melanoma\n             (molecularly confirmed using Cobas assay or a comparable Food and Drug Administration\n             [FDA]-approved assay) that is metastatic or unresectable, have received prior BRAF or\n             BRAF and mitogen-activated protein kinase (MEK) inhibitor therapy, and for which\n             standard curative measures do not exist or are no longer effective\n\n          -  Patients must have measurable disease, defined as at least one lesion that can be\n             accurately measured in at least one dimension (longest diameter to be recorded for\n             non-nodal lesions and short axis for nodal lesions) as >= 20 mm with conventional\n             techniques or as >= 10 mm with spiral computed tomography (CT) scan, magnetic\n             resonance imaging (MRI), or calipers by clinical exam\n\n          -  Prior therapy is allowed; patients may have received any number of prior lines of\n             therapy including treatment with a BRAF and/or MEK inhibitor\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status =< 1 (Karnofsky >= 70%)\n\n          -  Life expectancy of greater than 3 months\n\n          -  Leukocytes >= 3,000/mcL\n\n          -  Absolute neutrophil count >= 1,200/mcL\n\n          -  Hemoglobin >= 9 g/dl (patients may be transfused to this level)\n\n          -  Platelets >= 100,000/mcL\n\n          -  Total bilirubin =< 1.5 x institutional upper limit of normal\n\n          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase\n             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])\n             =< 2.5 x institutional upper limit of normal\n\n          -  Prothrombin time (PT) >= 1.3 x upper limit of normal (ULN)\n\n          -  International normalized ratio (INR) >= 1.3 x ULN\n\n          -  Partial thromboplastin time (PTT) >= 1.3 x ULN\n\n          -  Creatinine within normal institutional limits OR creatinine clearance >= 50\n             mL/min/1.73 m^2 for patients with creatinine levels above institutional normal\n\n          -  Patients must have a corrected QT (QTc) interval of less than 480 msec\n\n          -  Women of child-bearing potential and men must agree to use adequate contraception\n             prior to study entry, for the duration of study participation, and for 4 months after\n             completion of study drug administration; hormonal contraceptives may not be\n             effective; additional contraceptive measures should be in place such as barrier\n             method of birth control and abstinence; should a woman become pregnant or suspect she\n             is pregnant while she or her partner is participating in this study, she should\n             inform her treating physician immediately; men treated or enrolled on this protocol\n             must also agree to use adequate contraception prior to the study, for the duration of\n             study participation, and 4 months after completion of study drug administration\n\n          -  Ability to understand and the willingness to sign a written informed consent document\n\n          -  Able to swallow and retain oral medication\n\n        Exclusion Criteria:\n\n          -  Patients who have had immunotherapy, chemotherapy or radiotherapy within 4 weeks (6\n             weeks for nitrosoureas or mitomycin C) prior to entering the study\n\n          -  Patients must not have received prior AT13387\n\n          -  Patients who are receiving any other investigational agents\n\n          -  Patients must have no clinical evidence of brain metastasis; patients with prior\n             resection, stereotactic radiosurgery, or whole brain radiation for brain metastasis\n             are eligible, provided that disease is asymptomatic, corticosteroids are not needed,\n             and that imaging is stable for a least 4 weeks prior to enrollment in the study\n\n          -  History of allergic reactions attributed to compounds of similar chemical or biologic\n             composition to AT13387, dabrafenib, or trametinib, or excipients or to dimethyl\n             sulfoxide (DMSO)\n\n          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active\n             serious infection, symptomatic congestive heart failure, unstable angina pectoris,\n             cardiac arrhythmia, uncontrolled diabetes, or psychiatric illness/social situations\n             that would limit compliance with study requirements\n\n          -  Pregnant women are excluded from this study; breastfeeding should be discontinued if\n             the mother is treated with the study drugs\n\n          -  Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral\n             therapy are ineligible; appropriate studies will be undertaken in patients receiving\n             combination antiretroviral therapy when indicated\n\n          -  History of another malignancy; exception: patients who have been disease-free for 3\n             years, or patients with a history of completely resected non-melanoma skin cancer\n             and/or patients with indolent secondary malignancies, are eligible; subjects with any\n             malignancy with confirmed activating rat sarcoma (RAS) mutation are excluded;\n             prospective RAS testing is not required; however, if the results of previous RAS\n             testing are known, they must be used in assessing eligibility; consult the Cancer\n             Therapy Evaluation Program (CTEP) medical monitor if unsure whether second\n             malignancies meet the requirements specified above\n\n          -  History of interstitial lung disease or pneumonitis\n\n          -  Current use of a prohibited medication; the following medications or non-drug\n             therapies are prohibited:\n\n               -  Other anti-cancer therapy while on study treatment; (note: megestrol [Megace] if\n                  used as an appetite stimulant is allowed)\n\n               -  Concurrent treatment with bisphosphonates is permitted; however, treatment must\n                  be initiated prior to the first dose of study therapy; prophylactic use of\n                  bisphosphonates in patients without bone disease is not permitted, except for\n                  the treatment of osteoporosis\n\n               -  The concurrent use of all herbal supplements is prohibited during the study\n                  (including, but not limited to, St. John's wort, kava, ephedra [ma huang],\n                  ginkgo biloba, dehydroepiandrosterone [DHEA], yohimbe, saw palmetto, or ginseng)\n\n               -  Anticoagulants or antiplatelet agents except for low-dose, 81 mg aspirin\n\n          -  History or current evidence/risk of retinal vein occlusion (RVO) or central serous\n             retinopathy (CSR):\n\n               -  History of RVO or CSR, or predisposing factors to RVO or CSR (e.g., uncontrolled\n                  glaucoma or ocular hypertension, uncontrolled systemic disease such as\n                  hypertension, diabetes mellitus, or history of hyperviscosity or\n                  hypercoagulability syndromes)\n\n               -  Visible retinal pathology as assessed by ophthalmic exam that is considered a\n                  risk factor for RVO or CSR such as evidence of new optic disc cupping, evidence\n                  of new visual field defects, and intraocular pressure > 21 mm Hg\n\n          -  History or evidence of cardiovascular risk including any of the following:\n\n               -  Left ventricular ejection fraction (LVEF) < lower limit of normal (LLN)\n\n               -  A QT interval corrected for heart rate using the Bazett's formula QTcB >= 480\n                  msec\n\n               -  History or evidence of current clinically significant uncontrolled arrhythmias\n                  (exception: patients with controlled atrial fibrillation for > 30 days prior to\n                  randomization are eligible)\n\n               -  History of acute coronary syndromes (including myocardial infarction and\n                  unstable angina), coronary angioplasty, or stenting within 6 months prior to\n                  randomization\n\n               -  History or evidence of current >= class II congestive heart failure as defined\n                  by the New York Heart Association (NYHA) functional classification system\n\n               -  Treatment-refractory hypertension defined as a blood pressure of systolic > 140\n                  mmHg and/or diastolic > 90 mmHg which cannot be controlled by anti-hypertensive\n                  therapy Abnormal cardiac valve morphology (>= grade 2) documented by\n                  echocardiogram (subjects with grade 1 abnormalities [i.e., mild\n                  regurgitation/stenosis] can be entered on study); subjects with moderate\n                  valvular thickening should not be entered on study\n\n          -  Active hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (patients with\n             chronic or cleared HBV and HCV infection are eligible)\n\n          -  Anti-cancer therapy including chemotherapy, immunotherapy, radiotherapy, hormonal\n             (with the exception of hormones for thyroid conditions or estrogen replacement\n             therapy [ERT]), and other investigational agents will not be allowed within 14 days\n             prior to the first dose of AT13387, dabrafenib and trametinib; additionally,\n             participants must have recovered to less than grade 2 clinically significant adverse\n             effect(s)/toxicity(ies) of the previous therapy; biologics will not be allowed within\n             30 days prior to, or during, study drug administration\n\n          -  Subject has a significant history of cardiovascular disease (e.g., myocardial\n             infarction [MI], thrombotic or thromboembolic event in the last 6 months)\n\n          -  A history of glucose-6-phosphate dehydrogenase (G6PD) deficiency"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "38", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02097225", 
            "org_study_id": "NCI-2014-00615", 
            "secondary_id": [
                "NCI-2014-00615", 
                "9557", 
                "9557", 
                "U01CA062490", 
                "P30CA006516"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment (dabrafenib, trametinib, Hsp90 inhibitor AT13387)", 
                "description": "Given PO", 
                "intervention_name": "dabrafenib", 
                "intervention_type": "Drug", 
                "other_name": [
                    "BRAF inhibitor GSK2118436", 
                    "GSK-2118436A", 
                    "GSK2118436", 
                    "Tafinlar"
                ]
            }, 
            {
                "arm_group_label": "Treatment (dabrafenib, trametinib, Hsp90 inhibitor AT13387)", 
                "description": "Given PO", 
                "intervention_name": "trametinib", 
                "intervention_type": "Drug", 
                "other_name": [
                    "GSK1120212", 
                    "JTP-74057", 
                    "Mekinist"
                ]
            }, 
            {
                "arm_group_label": "Treatment (dabrafenib, trametinib, Hsp90 inhibitor AT13387)", 
                "description": "Given IV", 
                "intervention_name": "Hsp90 inhibitor AT13387", 
                "intervention_type": "Drug", 
                "other_name": "AT13387"
            }, 
            {
                "arm_group_label": "Treatment (dabrafenib, trametinib, Hsp90 inhibitor AT13387)", 
                "description": "Correlative studies", 
                "intervention_name": "pharmacological study", 
                "intervention_type": "Other", 
                "other_name": "pharmacological studies"
            }, 
            {
                "arm_group_label": "Treatment (dabrafenib, trametinib, Hsp90 inhibitor AT13387)", 
                "description": "Correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 30, 2014", 
        "location": [
            {
                "contact": {
                    "email": "Geoffrey.Gibney@moffitt.org", 
                    "last_name": "Geoffrey T. Gibney", 
                    "phone": "813-745-8581"
                }, 
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33612"
                    }, 
                    "name": "H. Lee Moffitt Cancer Center and Research Institute"
                }, 
                "investigator": {
                    "last_name": "Geoffrey T. Gibney", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "rsullivan7@partners.org", 
                    "last_name": "Ryan J. Sullivan", 
                    "phone": "617-724-4000"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02114"
                    }, 
                    "name": "Massachusetts General Hospital Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Ryan J. Sullivan", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase I Study of AT13387 in Combination With Dabrafenib and Trametinib in BRAF-Inhibitor Resistant Patients With BRAF-Mutant Melanoma", 
        "other_outcome": {
            "description": "Descriptive statistics including mean, standard deviation, coefficient of variation, geometric mean, median, minimum and maximum will be computed for each pharmacokinetic variable; descriptive statistics for natural-log transformed pharmacokinetic variables will also be provided.", 
            "measure": "Pharmacokinetic parameters (maximal plasma or serum concentration [Cmax], area under the curve to the last collection point [AUClast], area under the curve for dose interval [AUC0-t], and time of maximal concentration [Tmax])", 
            "safety_issue": "No", 
            "time_frame": "Course 1, days 1 and 15 (pre-dose, 1, 2, 4, 6, 8, 24 hour post-dose) and day 1 in courses 2, 4, 8, and 12 (pre-dose)"
        }, 
        "overall_official": {
            "affiliation": "Dana-Farber Cancer Institute", 
            "last_name": "Ryan Sullivan", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Toxicities will be graded according to the National Cancer Institute Common Toxicity Criteria for Adverse Events version 4.0. Toxicity rates will be summarized with a 90% exact binomial confidence interval.", 
            "measure": "MTD of Hsp90 inhibitor AT13387 in combination with dabrafenib and trametinib, defined as the highest dose level at which 0 or 1 of six patients has experienced a dose limiting toxicity", 
            "safety_issue": "Yes", 
            "time_frame": "28 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02097225"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The response rate will be presented as a point estimate with a 90% exact binomial confidence interval.", 
                "measure": "ORR, defined as the proportion of patients with complete or partial response as their best response to therapy assessed according to Response Evaluation Criteria in Solid Tumors version 1.1", 
                "safety_issue": "No", 
                "time_frame": "The date of first dose of trial therapy and the date of objectively documented disease progression or cessation of trial therapy, whichever occurs first, assessed up to 28 days after end of treatment"
            }, 
            {
                "description": "The distribution of PFS will be summarized using the product-limit method of Kaplan-Meier.", 
                "measure": "PFS", 
                "safety_issue": "No", 
                "time_frame": "Time from start of treatment to time of progression or death, whichever occurs first, assessed up to 28 days after end of treatment"
            }, 
            {
                "description": "Median times for each endpoint will be presented with two-sided, 90% confidence intervals estimated using log(-log[survival]) methodology.  Kaplan-Meier estimates of 6-month PFS will also be presented with two-sided, 90% confidence intervals.", 
                "measure": "PFS", 
                "safety_issue": "No", 
                "time_frame": "Time from start of treatment to time of progression or death, whichever occurs first, assessed at 6 months"
            }, 
            {
                "description": "The distribution of OS will be summarized using the product-limit method of Kaplan-Meier. Kaplan-Meier estimates of 1-year OS will also be presented with two-sided, 90% confidence intervals.", 
                "measure": "OS", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "The one-year disease-free survival after treatment will be estimated using the product-limit methods of Kaplan-Meier, and presented with 90% confidence intervals.", 
                "measure": "Disease-free survival", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }
        ], 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}